Ivosidenib as Post-HSCT Maintenance for AML

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-01-01

Summary

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

• Phase: PHASE2

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Servier
• Treatments: ivosidenib